These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19758683)

  • 1. Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository.
    Newcomb LF; Brooks JD; Carroll PR; Feng Z; Gleave ME; Nelson PS; Thompson IM; Lin DW
    Urology; 2010 Feb; 75(2):407-13. PubMed ID: 19758683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active surveillance with selective delayed intervention: walking the line between overtreatment for indolent disease and undertreatment for aggressive disease.
    Klotz LH
    Can J Urol; 2005 Feb; 12 Suppl 1():53-7; discussion 101-2. PubMed ID: 15780167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer.
    Klotz L
    J Urol; 2004 Nov; 172(5 Pt 2):S48-50; discussion S50-1. PubMed ID: 15535443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Active surveillance for localized prostate cancer].
    Drouin SJ; Rouprêt M; Hamdy F; Mottet N
    Prog Urol; 2010 Jun; 20 Suppl 3():S181-5. PubMed ID: 20620962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a 'number needed to treat' analysis.
    Klotz LH; Nam RK
    Can J Urol; 2006 Feb; 13 Suppl 1():48-55. PubMed ID: 16526983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer.
    Klotz L
    Nat Clin Pract Urol; 2005 Mar; 2(3):136-42; quiz 1 p following 149. PubMed ID: 16474710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active Surveillance for Prostate Cancer: How to Do It Right.
    Garisto JD; Klotz L
    Oncology (Williston Park); 2017 May; 31(5):333-40, 345. PubMed ID: 28512731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer.
    Klotz L
    Eur Urol; 2005 Jan; 47(1):16-21. PubMed ID: 15582244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
    Choo R; Klotz L; Danjoux C; Morton GC; DeBoer G; Szumacher E; Fleshner N; Bunting P; Hruby G
    J Urol; 2002 Apr; 167(4):1664-9. PubMed ID: 11912384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.
    Klotz L; Vesprini D; Sethukavalan P; Jethava V; Zhang L; Jain S; Yamamoto T; Mamedov A; Loblaw A
    J Clin Oncol; 2015 Jan; 33(3):272-7. PubMed ID: 25512465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance.
    Loblaw A; Zhang L; Lam A; Nam R; Mamedov A; Vesprini D; Klotz L
    J Urol; 2010 Nov; 184(5):1942-6. PubMed ID: 20846681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active surveillance with selective radical treatment for localized prostate cancer.
    van As NJ; Parker CC
    Cancer J; 2007; 13(5):289-94. PubMed ID: 17921727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transurethral resection of the prostate for patients with Gleason score 6 prostate cancer and symptomatic prostatic enlargement: a risk-adaptive strategy for the era of active surveillance.
    Koo KC; Park SU; Rha KH; Hong SJ; Yang SC; Hong CH; Chung BH
    Jpn J Clin Oncol; 2015 Aug; 45(8):785-90. PubMed ID: 25979243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-risk prostate cancer can and should often be managed with active surveillance and selective delayed intervention.
    Klotz L
    Nat Clin Pract Urol; 2008 Jan; 5(1):2-3. PubMed ID: 18043601
    [No Abstract]   [Full Text] [Related]  

  • 15. [The significance of PSA density as predictive factor in Afro-Caribbean patients eligible for active surveillance by the French protocol criteria].
    Loiselle A; Senechal C; Nevoux P; Benazzouz H; Bhakkan-Mambir B; Casenave J; Gourtaud G; Fofana M; Blanchet P
    Prog Urol; 2014 May; 24(6):327-33. PubMed ID: 24821554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
    Krakowsky Y; Loblaw A; Klotz L
    J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active surveillance for prostate cancer: can we modernize contemporary protocols to improve patient selection and outcomes in the focal therapy era?
    Tay KJ; Mendez M; Moul JW; Polascik TJ
    Curr Opin Urol; 2015 May; 25(3):185-90. PubMed ID: 25768694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Who bears the greatest burden of aggressive treatment of indolent prostate cancer?
    Mahal BA; Cooperberg MR; Aizer AA; Ziehr DR; Hyatt AS; Choueiri TK; Hu JC; Sweeney CJ; Beard CJ; D'Amico AV; Martin NE; Orio PF; Trinh QD; Nguyen PL
    Am J Med; 2015 Jun; 128(6):609-16. PubMed ID: 25644324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active surveillance with selective delayed intervention for favorable risk prostate cancer.
    Klotz L
    Urol Oncol; 2006; 24(1):46-50. PubMed ID: 16414494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.